

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:  
Drug Safety Labeling Changes -  
Kenalog (triamcinolone acetonide) injectable suspension**

According to MedWatch, FDA notified healthcare professionals that the WARNINGS text for Kenalog has been updated. The following sentences have been added to the labeling:

**WARNINGS**

***General***

- Results from one multicenter, randomized, placebo controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial trauma who were determined not to have other clear indications for corticosteroid treatment. High doses of systemic corticosteroids, including Kenalog, should not be used for the treatment of traumatic brain injury.

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm201164.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.